Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 76.91M P/E - EPS this Y -4.30% Ern Qtrly Grth -
Income -41.47M Forward P/E -1.24 EPS next Y -9.30% 50D Avg Chg 10.00%
Sales 488k PEG - EPS past 5Y - 200D Avg Chg 8.00%
Dividend N/A Price/Book 0.79 EPS next 5Y - 52W High Chg -48.00%
Recommedations 1.70 Quick Ratio 7.20 Shares Outstanding 44.68M 52W Low Chg 42.00%
Insider Own 7.56% ROA -28.69% Shares Float 41.29M Beta 1.97
Inst Own 15.20% ROE -47.07% Shares Shorted/Prior 3.41M/1.15M Price 1.71
Gross Margin - Profit Margin - Avg. Volume 154,138 Target Price 10.50
Oper. Margin -6,623.08% Earnings Date May 2 Volume 204,678 Change -7.57%
About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Cardiff Oncology, Inc. News
04/08/24 Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
03/06/24 Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
03/03/24 Cardiff Oncology Full Year 2023 Earnings: Beats Expectations
03/01/24 Cardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial Results
02/29/24 Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
02/29/24 Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
02/29/24 Cardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)
02/26/24 Cardiff Oncology to Present at the Cowen 44th Annual Health Care Conference
02/22/24 Cardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business Update
01/17/24 Cardiff Oncology Announces Publication of Data from Phase 1b study in second-line KRAS-mutated mCRC in Clinical Cancer Research
11/20/23 Cardiff Oncology to Present at the 35th Annual Piper Sandler Healthcare Conference
11/02/23 Cardiff Oncology Reports Third Quarter 2023 Results and Provides Business Update
10/31/23 We're Keeping An Eye On Cardiff Oncology's (NASDAQ:CRDF) Cash Burn Rate
10/26/23 Cardiff Oncology to Report Third Quarter 2023 Financial Results and Provide Business Update
09/26/23 Cardiff Oncology Announces Positive Clinical Data in Pancreatic Cancer and Small Cell Lung Cancer, including Single-Agent Activity from Onvansertib Monotherapy
09/05/23 Cardiff Oncology to Present at Upcoming Investor Conferences in September
08/09/23 Cardiff Oncology Reports Second Quarter 2023 Results and Provides Business Update
08/07/23 Cardiff Oncology Announces New Lead Program in First-Line Metastatic Colorectal Cancer and Expanded Pfizer Relationship
04:09 PM Cardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
06/05/23 Cardiff Oncology to Present at the Jefferies Healthcare Conference
CRDF Chatroom

User Image Purrito Posted - 11 hours ago

Crdf

User Image Moneytimeeeeee Posted - 14 hours ago

$ABVC $CRDF $RCAT $RXRX fk meeee I had a. 60% + mover too early and left when they shakes out the stop losses

User Image Alita300 Posted - 14 hours ago

$CRDF looking the continual give and take and trade blocks, this does smells of algos and MM. Stocks generally move when they need to like we did from $1.50 to 6. That was a needed shift and I suspect there is another push coming with more market news to push a leg up to 8-10$. I don’t see this camping out at 4 until data releases in early mid July. I do think as June 30 approaches, initial scans will begin to be consolidated and reviewed. If that data is positive across a growing 40+ patients, I see a scenario for a significant jump on data leak or direct BO

User Image spartaksus Posted - 16 hours ago

$CRDF we are all like Brett McBain- the guy who did his research and set everything up and then just waited patiently. Probably only older bulls here watched that movie :)

User Image nowandagain Posted - 17 hours ago

$CRDF just about the stupidest acting stock around

User Image The_Self_Made_Fool Posted - 17 hours ago

$CRDF, did yah buy the dip its delicious. Like these legs.

User Image Stocks4thought Posted - 17 hours ago

$CRDF Almost past trucker pull off.

User Image Alita300 Posted - 17 hours ago

$CRDF There are stocks you trade based on academics and patterns and the like and then there are stocks you invest for value. CRDF is too risky to day trade unless you have both a 50,000 share long term position and another pot of short money. Anything less than 50,000 and you are not taking advantage of the opportunity in front of you.

User Image Stu52 Posted - 18 hours ago

$CRDF $RANI $INDP $ESPR $MAIA ….no , not PFE !!! @RallyRaiders owns all these floats , lol !!!

User Image Stu52 Posted - 18 hours ago

$CRDF Gee ..need 450 on the DOW ???? @Stocks4$hit

User Image Okenrav Posted - 18 hours ago

$CRDF yah! Because probably $PFE owns the bulk of the float.

User Image JTonelli Posted - 19 hours ago

$CRDF I am honestly surprised this not down a lot more than it is. Probably would be worse if the rest of the market was red or even flat. There is so little buying that sellers are not even being challenged. Shorts were covering, but have started to borrow again. Why not? Not many positions you can take in the market that is nearly guaranteed profit. But this one....after a recent big spike by buyers with no plans to support the price....its just too easy to ignore. So little buying right now that I think this will be in the 3's before the end of the day. I cant help but wonder how much of the March gain will actually stick. When I first bought in here I watched this drop from 21 all the way below 1. Dropping from the 5's back to 1 isnt even a newsworthy sell down here. Get some free cash ready for cheap shares

User Image HoHoHoHum Posted - 19 hours ago

$CRDF testing 50 day ma. frankly not surprised. will emerge stronger. added a few.

User Image JTonelli Posted - 19 hours ago

$CRDF I swear they do this on certain days just to flex and show their level of control of the price. The entire market is bright green and the bio sector and XBI are having one of its best days in months. Basically everything is bright green today and this has barely seen a green candle since the market opened. Should also give you a better idea of how little influence bulls have on the SP during normal trading

User Image PensionPulse Posted - 19 hours ago

$CRDF Going back to $3

User Image pharmde Posted - 20 hours ago

$CRDF loaded +775 shares

User Image Indo Posted - 20 hours ago

$CRDF with a 49K volume they dropped it down .19

User Image User123321 Posted - 20 hours ago

$CRDF Now touched the 50% fib zone 3.88-4.12 based on .94-6.82 and .94-7.29. Could get much uglier. Not a prediction but if $4 and 3.88 break the 61.8% zone is 3.19-3.37. Holding but this is no given when data is involved. We’ve all seen it both good and bad. Data likely by August or September’s end.

User Image JTonelli Posted - 20 hours ago

$CRDF Ouch. That one was a tough price break. Now below support at 4.31. Not really sure where the next level of support is at and Im not going to to take the time to figure it out. This is when its important to have a price target or long term goal. There is a lot of history that shows how this ticker normally trades and this appears to be back to its norm. Buyers loaded up during the run up and are no longer actively purchasing. They are waiting for the next update. Shorts have always taken advantage of the times between material updates. We have a much smaller market of buyers compared blue chip stocks that have institutions and big daily buyers. Just dont do anything stupid if this starts to get really ugly.......because it definitely might......and because the trend can change instantly with one huge buy like it did in March. Looking like we have a lot of red in our future until our next update. Get some more shares cheap and hold and forget

User Image Butwhyarsh Posted - 20 hours ago

$CRDF what caused the sudden dip?

User Image Tru_Green Posted - 1 day ago

$CRDF : Cardiff has updated the Corporate Presentation on their website... 80 pages of must reading for all longs (and any shorts). One important new graphic on why the FDA's recommendation to move from second line to first line is so significant: onvansertib has gone from 9.5k annual eligible U.S. patients in second line to now 48k in first line, for metastatic colorectal cancer alone – an indication in dire need of new therapies, with the standard of care not having improved in almost twenty years. Overall, the document covers the bull case comprehensively. This is looking like a double-digit stock within a matter of months. https://cardiffoncology.com/

User Image Okenrav Posted - 1 day ago

$CRDF 14% 'tutes? Who owns the bulk of the float? $PFE?

User Image spartaksus Posted - 1 day ago

$CRDF I think we will get some shockingly positive news during next 1Q call.

User Image Stu52 Posted - 1 day ago

$CRDF…..go ahead , make my day …here since Dec 2023 and you are a fcukin guru. What they do, kick your sorry a$$ of Reddit and Yahoo , lol …. I don’t do yahoo, but fits your inferiority complex that I am there , lol …

User Image Vandenberg23 Posted - 1 day ago

$CRDF Sale prediction is 3x annual sales of Bev

User Image Stocks4thought Posted - 1 day ago

$CRDF Sooner or later ARROW SMITH- walk the dog$

User Image pharmde Posted - 1 day ago

$CRDF if we get bought out, profits go into Pfizer. or whoever acquires it

User Image JTonelli Posted - 1 day ago

$CRDF Remember when I was a bit overdramatic in March about how many days and hours in a row this spent in the green? Just full on green for massive stretches at a time. This is why I was so excited..... because for about 3 years it was the exact opposite. Basically red all the time without ever flashing green for a second. Now we are back to the norm.....BUT remember this same price action led to a gain of over 200% in one month. Now we know we have some promising things going on in the background. This is a much easier hold now. Average up or down when you can. Im thinking this becomes the most lucrative investment most of us have ever made and I think that happens in the next 365 days.

User Image Tru_Green Posted - 1 day ago

$CRDF : In the onvansertib Phase 1b/2 trial, there were 66 patients with 15 being bev-naive and 11 of those 15 (73%) achieved an objective response with reductions in tumor size up to 100%. In Cardiff's Phase 2 ONSEMBLE trial, 2 of 4 bev-naive patients achieved ORR with progressive reductions in tumor size – and it could potentially have been 3 of 4, but one patient stopped taking onvansertib (for unrelated reasons) and their tumor grew back. In the new CRDF-004 first-line trial (n=90) conducted in partnership with Pfizer, 100% of the patients taking oral onvansertib are bev-naive and the company expects the initial readout for half the patients by mid-2024. Contingent upon CRDF-004, Cardiff will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent. The FDA has agreed that ORR at an interim point is an acceptable endpoint to pursue accelerated approval of onvansertib from the CRDF-005 trial. The company is aiming to start that trial early next year, CEO Erlander said.

User Image Stu52 Posted - 2 days ago

$CRDF ..look like you beat me on the bus, I’ll take another thanks

Analyst Ratings
HC Wainwright & Co. Buy Mar 6, 24
Piper Sandler Overweight Mar 1, 24
HC Wainwright & Co. Buy Aug 11, 23
HC Wainwright & Co. Buy Aug 8, 23
HC Wainwright & Co. Buy May 9, 23
HC Wainwright & Co. Buy Mar 29, 23
HC Wainwright & Co. Buy Mar 7, 23
HC Wainwright & Co. Buy Sep 16, 22
Piper Sandler Overweight Sep 13, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
PACE GARY W Director Director Dec 19 Buy 1.37 30,000 41,100 697,761 12/19/23
Erlander Mark Chief Executive Offi.. Chief Executive Officer Nov 25 Buy 1.43 10,000 14,300 24,481 11/29/22
White Lale Director Director Sep 19 Buy 1.635 15,000 24,525 113,788 09/20/22
TANNENBAUM RENEE P Director Director Sep 15 Buy 1.72 10,000 17,200 10,000 09/19/22
PACE GARY W Director Director Sep 15 Buy 1.71 150,000 256,500 644,811 09/19/22
Levine James E. Chief Financial Offi.. Chief Financial Officer Sep 16 Buy 1.557 30,000 46,710 60,000 09/19/22
Levine James E. Chief Financial Offi.. Chief Financial Officer Sep 13 Buy 6.48 30,000 194,400 30,000 09/13/21
Kelemen Vicki Exec. VP and COO Exec. VP and COO Nov 25 Option 2.48 35,321 87,596 40,375 11/25/20
Kelemen Vicki Exec. VP and COO Exec. VP and COO Nov 25 Sell 18.6 35,321 656,971 5,054 11/25/20